Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Chromosome 8 gain is associated with high-grade transformation in MPNST
Carina Dehner, … , Jack F. Shern, Angela C. Hirbe
Carina Dehner, … , Jack F. Shern, Angela C. Hirbe
Published February 16, 2021
Citation Information: JCI Insight. 2021;6(6):e146351. https://doi.org/10.1172/jci.insight.146351.
View: Text | PDF
Research Article Genetics Oncology

Chromosome 8 gain is associated with high-grade transformation in MPNST

  • Text
  • PDF
Abstract

One of the most common malignancies affecting adults with Neurofibromatosis type 1 (NF1) is the malignant peripheral nerve sheath tumor (MPNST), an aggressive and often fatal sarcoma that commonly arises from benign plexiform neurofibromas. Despite advances in our understanding of MPNST pathobiology, there are few effective therapeutic options, and no investigational agents have proven successful in clinical trials. To further understand the genomic heterogeneity of MPNST, and to generate a preclinical platform that encompasses this heterogeneity, we developed a collection of NF1-MPNST patient-derived xenografts (PDX). These PDX were compared with the primary tumors from which they were derived using copy number analysis, whole exome sequencing, and RNA sequencing. We identified chromosome 8 gain as a recurrent genomic event in MPNST and validated its occurrence by FISH in the PDX and parental tumors, in a validation cohort, and by single-cell sequencing in the PDX. Finally, we show that chromosome 8 gain is associated with inferior overall survival in soft-tissue sarcomas. These data suggest that chromosome 8 gain is a critical event in MPNST pathogenesis and may account for the aggressive nature and poor outcomes in this sarcoma subtype.

Authors

Carina Dehner, Chang In Moon, Xiyuan Zhang, Zhaohe Zhou, Chris Miller, Hua Xu, Xiaodan Wan, Kuangying Yang, Jay Mashl, Sara J.C. Gosline, Yuxi Wang, Xiaochun Zhang, Abigail Godec, Paul A. Jones, Sonika Dahiya, Himanshi Bhatia, Tina Primeau, Shunqiang Li, Kai Pollard, Fausto J. Rodriguez, Li Ding, Christine A. Pratilas, Jack F. Shern, Angela C. Hirbe

×

Figure 5

Survival analysis based on gene expression.

Options: View larger image (or click on image) Download as PowerPoint
Survival analysis based on gene expression.
(A) Kaplan-Meir curves showi...
(A) Kaplan-Meir curves showing the association of Chr8q gain with inferior overall survival in patients with soft-tissue sarcomas. Significance was assessed by log-rank test and the Cox proportional hazards model. (B) Survival analysis showing difference in overall survival in case of increased expression of RECQL4, SOX17, HEY1, MYC, RAD21, or UBR5. TPM, transcripts per million. Significance was assessed with the Cox proportional hazards model.

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts